|Description||JNJ 55511118 has been found to be an AMPA receptor modulator and could probably be used as an anticonvulsant.|
|Purity||≥98% by HPLC|
|Synonyms||JNJ-55511118; JNJ 55511118; JNJ55511118; 5-[2-Chloro-6-(trifluoromethoxy)phenyl]-1,3-dihydro-2H-benzimidazol-2-one|
CX 614 has been found to be an AMPA modulator and has also been found to be an ampakine drug facilitating activation of glutamatergic AMPA receptors.
LY 404187 is an allosteric modulator of AMPA receptors (IC50 = 0.15μM, 0.21μM, 1.66μM and 5.65 μM for GluA2i, GluA4i, GluA3i and GluA1i, respectively).
SYM 2206 is a potent and noncompetitive AMPA receptor antagonist (IC50 = 2.8 μM ) that exhibits anticonvulsant activity in vivo. SYM 2206 acts allosterically at...
LY-326325, a decahydroisoquinaline derivative, has been found to be an AMPA receptor antagonist and was once studied for neuroprotection.
It is one of a series of AMPA modulators for the potential treatment of Alzheimer's disease, schizophrenia, and mild cognitive impairment (MCI). An ampakine dru...
(R)-AMPA is an inactive enantiomer of AMPA, which has been found to be a definitive agonist of the AMPA glutamatergic ionotropic receptor.
GYKI 53655 hydrochloride
GYKI 53655 hydrochloride is a non-competitive AMPA and kainate receptor antagonist displaying anticonvulsant activity. It also acts as a blocker of GluK3 homome...
GYKI-53784, a dioxolbenzene derivative, has been found to be a AMPA receptor antagonist that could block excitotoxicity and decrease auditory nerve activity at ...